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Acute myeloid leukemia (AML) is characterized by an increase in the number of myeloid
cells in the marrow. This, together with the
arrest of these cells, may result in hematopoietic insufficiency, such as granulocytopenia,
thrombocytopenia or anemia.1 Since there is
no cancer registry in Pakistan, a study carried
out at our center in 2002 reported 74 adult
patients with acute myeloid leukemia during
an 8-year study period.2 Most younger patients
with acute myeloid leukemia achieve complete
remission with induction and consolidation
chemotherapy regimens. However, these
remissions are not sustainable even for
patients who achieve complete remission 1
(CR1). The invariable risk of relapse requires
consolidation with allogeneic stem cell transplant.3
In developing countries, non-malignant diseases such as thalassemia major and aplastic
anemia account for the largest number of
transplant procedures;4 this is in complete
contrast to the situation in developed countries. Here in Pakistan, treatment of AML is
managed on an individual basis, since the cost
of standard uncomplicated transplant ranges
from $25,000-$30,000. Most of the transplants
performed are privately funded, but philanthropists generally prefer to invest in pathologies that have a better overall survival. This
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We report a case series of 12 patients with
acute myeloid leukemia who underwent allogeneic stem cell transplant with a matched
related donor. Male to female ratio was 1:1.
The main complication post-transplant was
graft-versus-host disease (n=7 patients).
Transplant-related mortality involved one
patient; cause of death was multi-organ failure. After a median follow up of 36.0±11.3
months, overall survival was 16%.
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also means that patients come to the attention
of the physician late in their disease course.
The European Group for Blood and Marrow
Transplantation 2004 survey reported acute
myeloid leukemia to be the most common indication for allogeneic hematopoietic stem cell
transplant.5 The procedure offers a double benefit as the preparative regimen in myeloablative doses eradicates the leukemic cells and
this is followed by the post-transplant graftversus-leukaemia effect.
A number of retrospective and prospective
studies have identified risk factors that play a
role in determining post-transplant survival of
patients with AML. The most important determinants of standard, intermediate and highrisk patient populations include gender, presenting white blood cell counts, and impact of
cytogenetics.6
From 1984 till 2001, the Bordeaux Grenoble
Marseille Toulouse intergroup followed a
proactive strategy of performing early allogeneic stem cell transplant as part of consolidation in patients under the age of 45 years
who had an HLA (human leukocyte antigen)
identical sibling donor.7 For patients without
an HLA matched donor, further chemotherapy
courses were given and these changed over the
years on the basis of the experience gained
from different studies. The results showed that
allogeneic stem cell transplant (alloSCT) provided a survival advantage for an intermediate
risk group. AlloSCT performed early in the disease course was not the optimal treatment for
high-risk patients. Neither did it offer any
advantage over intensive chemotherapy to lowrisk patients. We report our experience of 12
patients with acute myeloid leukemia
(relapsed and CR1) who underwent allogeneic
stem cell transplant over a 7-year period. These
results show the survival of patients from a
developing country where stem cell transplant
is an expensive approach that is beyond the
financial means of most of the population.
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Materials and Methods
This study ran from April 2004 till June 2012
and included patients with acute myeloid
leukemia eligible for bone marrow transplant.
Other inclusion criteria were: age up to 60
years, diagnosis of AML based on the French
American British classification excluding
acute promyelocytic leukemia, no history of
myelodysplasia or previous cytotoxic
therapy/radiation, and absence of concomitant
disease.
Patients received induction chemotherapy
with daunorubicin 45 mg/m2 intravenously on
Days 1-3 and cytarabine 100 mg/m2 infusion on
Days 1-7. Consolidation was given with high[Hematology Reports 2012; 4:e25]

dose cytarabine at a dose of 3 gm/m2 administered by a 2-h infusion every 12 h on Days 1, 3
and 5. The most frequently used salvage
chemotherapy regimen included idarubicin,
fludarabine, cytarabine and G-CSF. Patients
under the age of 60 years with an HLA matched
sibling donor were then admitted to the bone
marrow transplant unit.
After a baseline pre-transplant workup of
the donor and patient, peripheral blood stem
cells were collected using a COBE spectra cell
separator. All donors received granulocyte
colony-stimulating factor at a dose of 10
μg/kg/day.
The two conditioning regimens used for
patients undergoing stem cell transplant were:
i) busulfan 4 mg/kg/day for four days along
with cyclophosphamide 60 mg/kg/day for two
days; ii) cyclophosphamide 60 mg/kg/day for
two days along with fractionated total body
irradiation at a dose of 1.5 Gy twice daily for
four days.
Standard prophylaxis was provided with
ciprofloxacin (500 mg twice daily or 20-30
mg/kg/two divided doses), fluconazole (200 mg
once daily or 6 mg/kg/day) and valaciclovir
(500 mg twice daily or 10 mg/kg/twice daily);
this was started on Day 5 in all patients. All
patients were given a neutropenic diet and
admitted to a protective isolation environment
equipped with a high-efficiency particulate air
filter, positive pressure and laminar airflow
ventilation.
Graft-versus-host disease (GVHD) prophylaxis was given with cyclosporine starting at
Day -1 (2.5 mg/kg q12-hourly) with regular
monitoring of drug levels, methotrexate
administered on Day +1 (15 mg/m2), Day +3
(10 mg/m2) and Day +6 (10 mg/m2), and irra[page 95]
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Hemoglobin (g/dL)
White blood cell count (¥109)
Platelets (¥109)

9.6±1.9 (7.8-12.8)
127.7±118 (1.8-292)
32±11 (19-45)

nation of chemotherapy and allogeneic stem
cell transplant; ii) cytogenetic abnormalities
have been seen to be the most important predictor of outcome. 8,9
Here we have reported the outcome of 12
patients with AML who underwent allogeneic
stem cell transplant. Due to the small size, firm
conclusions cannot be made from this study.
There was no gender predilection observed
although previous studies had reported an
increased frequency in males. A study carried
out in 2005 by Appelbaum et al.10 in 968
patients showed no change in gender ratio
with age. AML is primarily seen in adults and,
although in this study we stratified patients
according to age for transplant eligibility, the
overall median age for AML in this region is
relatively low compared to that reported in the
international literature. The median age in
this study was 26.5 years; this is in line with a
previous study carried out in our center in
2005. Similarly, another center in Pakistan has
reported even lower age values, i.e. 21 years,
when the authors evaluated the treatment outcome of de novo AML.11 Data reported in two
studies from developed countries now show a
median age of 52 and 67 years, respectively.12,13 The reason for this difference is difficult
to ascertain; however, it may be a true ethnic
or geographical variation as seen in the presentation of other diseases from our region.
Peripheral blood progenitor cells (PBSC)
are now being used for almost all hematopoietic transplant procedures. These cells have
higher numbers of CD34 and T lymphocytes.14
PBSC were used in all our patients. As a result,
11 of 12 patients engrafted. The only patient
with graft failure died from multi-organ failure
secondary to sepsis.
Grade I acute GVHD is generally understood
to be associated with an improved post-transplant outcome. Grades above this result in a
worse overall survival since the beneficial effect
of suppressing leukemia relapse is complicated
by the morbidity and mortality associated with
GVHD.15 Four patients in our study developed
grade II acute GVHD. However, the cause of
death in all these patients was disease relapse
rather than the GVHD itself. In our group of
patients, 3 underwent transplant procedure in
CR1 (increased white blood cell counts, n=2;
Philadelphia positive AML, n=1) whereas the
remaining patients were in CR2. Small retrospective studies (less than 100 patients) have

been reported for patients with AML not in
remission undergoing stem cell transplant procedure. These studies have reported long-term
survival rates of 20-30%.16 In 2000, Michallet et
al.17 reported outcome of 379 patients. Of these,
230 received transplants with active disease. As
expected, patients who underwent re-induction
therapy first and achieved a complete remission
did significantly better, with an overall survival
of 32%. In 2010, the Center for International
Blood and Bone Marrow Transplant Research
reported the largest and most complete analysis
of outcome of AML patients undergoing stem
cell transplant.18 The study included more than
2000 patients and overall survival at three years
was 19%. In our series, overall survival was
16%. Although our subset is small, the results
are still comparable with the overall survival of
AML in patients of developed countries.

on

e

us

al

ci

-c

on

N

Discussion
Over the last decade, two important observations have been made with regard to treatment
of acute myeloid leukemia: i) sustainable
remission rates can be obtained with a combi[page 96]
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From April 2004 till June 2012, 12 patients
with acute myeloid leukemia received allogeneic stem cell transplant procedure. Male to
female ratio was 1:1. Ten patients showed no
cytogenetic abnormalities. One patient had
Philadelphia positive acute myeloid leukemia
while one had multiple abnormalities
(Monosomy 8 and t11q; 23). Laboratory parameters of these patients are listed in Table 1.
Two patients received gender mismatched
transplant while 3 had ABO blood group mismatched donors. All patients and donors were
cytomegalovirus positive. Conditioning with
busulfan and cyclophosphamide was given in
10 patients while the rest received total body
irradiation based therapy. Median age was
26.5±11.5 years (range 9-50 years). One
patient was under 15 years of age, while all the
other patients were adults. Mean mononuclear
cell count was 5.6¥108/kg (range 3.58.3¥108/kg). Stem cell source was peripheral
blood progenitor cells for all patients.
Engraftment was achieved in all except one
patient. Median time to engraftment (absolute
neutrophil count over 0.5¥109/L for three consecutive days) was 15.5±4.5 days (range 1026.3 days)
Post-transplant complications mainly
included GVHD. Grade II acute GVHD was
observed in 4 patients; chronic limited GVHD
was seen in one patient and extensive GVHD
in 2 patients, respectively. Biopsies were performed in n=4 patients for histopathological
confirmation. Eight patients developed febrile
neutropenia; of these, 2 had blood culture
positive for staphylococcus species and enterococcus.
Transplant-related mortality involved one
patient; cause of death was multi-organ failure. After a median follow up of 36.0±11.3
months, overall survival is 16%. Causes of
death include transplant-related mortality
(n=1), relapse of disease (n=7), fulminant
hepatic failure (n=1), and acute GVHD (n=1).
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Results

Table 1. Laboratory parameters of 12 patients with acute myeloid leukemia.
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diated blood products.
The main patients’ characteristics were statistically analyzed. Survival probabilities were
estimated using the Kaplan-Meier method.
Statistical analysis was performed using SPSS
software version 19 (Chicago, IL, USA).
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Conclusions
Acute myeloid leukemia is not the most
common indication for stem cell transplant.
Median patient age at presentation in our
study is relatively low compared to developed
countries. There was no gender preference
observed in our study. In Pakistan, the cost of
stem cell transplant procedures is beyond the
means of most of the population, and this
means that they come to the attention of physicians late in the disease course. In spite of
this, overall survival is still comparable to that
reported in the international literature.
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